How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£4.6bn

adjusted R&D investment in 2020

40

new medicines in development at FY 2020

17

new vaccines in development at FY 2020

 

 

Performance

We deliver growth by investing effectively in our business, developing our people and executing competitively.

£34bn

turnover in 2020

£9bn

adjusted operating profit in 2020

£5.4bn

free cash flow in 2020

£4bn

dividends paid in 2020

 

Trust

We are a responsible company - using our science and technology to address health needs, we are focused on making our products affordable and available, and being a modern employer. 

84%

employee engagement score on our latest employee survey

£250m

donated in 2020 to community health programmes

1st

in Access to Medicines Index since the assessment began in 2008